Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 0.49 |
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | BTK | Q06187 | 2/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | ABL2 | P42684 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL869298 | 0.89 | FAAH (0.42) | SRCEGFRBTKFAAHGPR119 | |
| SCHEMBL2374068 | 0.86 | BTK (0.46) | BTKTGFBR1FGFR1FGFR2FGFR4 | |
| SCHEMBL27889143 | 0.86 | BTK (0.52) | BTKTGFBR1FGFR1FGFR2FGFR4 | |
| SCHEMBL3751306 | 0.82 | PI4KA (0.50) | SRCEGFRTGFBR1FAAHFGFR1 | |
| SCHEMBL869280 | 0.82 | SRC (0.64) | SRCEGFRTGFBR1ABL1ABL2 | |
| SCHEMBL16236647 | 0.80 | TGFBR1 (0.52) | SRCEGFRBTKTGFBR1ABL1 | |
| SCHEMBL3750043 | 0.79 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1 | |
| SCHEMBL17406898 | 0.78 | TGFBR1 (0.51) | SRCEGFRBTKTGFBR1ABL1 | |
| SCHEMBL19731470 | 0.77 | TGFBR1 (0.54) | SRCEGFRBTKTGFBR1ABL1 | |
| SCHEMBL19731469 | 0.76 | TGFBR1 (0.53) | SRCEGFRBTKTGFBR1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2549868-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-01-07 | — | — | EP | disclosed |
| US-8598156-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2549868-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| WO-2011119663-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018038-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | SRC 2497/4885EGFR 49/4885BTK 2336/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | SRC 2497/4885EGFR 49/4885BTK 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.